Who owns Analytik Jena AG?

Analytik Jena has been a wholly owned subsidiary of Switzerland's family controlled Endress+Hauser Group since a squeeze out completed around January to March 2016, when Endress+Hauser held 96.18 percent and paid EUR13.68 per remaining share. It delisted from the Frankfurt Stock Exchange on 27 March 2015.

Is Analytik Jena profitable?

No standalone profit figure is disclosed. Parent Endress+Hauser Group reported EUR3.72 billion revenue for FY2023 and said it maintained sales and profits at high levels in 2024, guiding mid single digit sales growth for 2025, but Analytik Jena's own contribution is not broken out.

Could AI replace Analytik Jena's lab instruments?

Unlikely in the near term. Analytik Jena's value sits in proprietary hardware like HR-CS AAS spectrometers and ICP-MS plasma sources plus regulatory method validation (USP, EPA). AI can augment its LIMS software (LABbase, readyLIMS) and spectral interpretation, but cannot replace physical instrumentation or installed-base service lock-in.

Who are Analytik Jena's biggest competitors?

Thermo Fisher Scientific (about $24.4 billion revenue), Agilent Technologies (about $4.9 billion), Shimadzu Corporation (about $3.2 billion), PerkinElmer, and Bruker Corporation, per a 2024-05-18 ICP-MS market report. These rivals are 15 to 170 times larger than Analytik Jena by revenue.

What is Analytik Jena's revenue?

The Analytik Jena legal entity reported EUR140.7 million revenue in FY2021 with 581 employees, per a Wikipedia infobox citation. This figure likely reflects the German parent entity only, not consolidated worldwide sales; no more recent standalone figure has been published.

Has Endress+Hauser considered spinning off Analytik Jena?

No divestiture or spin-off has been announced. A merger or restructuring transaction for Analytik Jena GmbH+Co. KG was registered in Germany's commercial register on 2026-06-11 under the Umwandlungsgesetz, with a six month creditor notice window, but this appears to be an internal reorganization, not a sale.

Biotech tools companies · subsidiary of Endress+Hauser AG (Reinach, Switzerland) · Germany

Analytik Jena AG

analytik-jena.com ↗

German maker of lab spectroscopy and ICP-MS/AAS instruments, owned by Endress+Hauser.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from December 2026 · Every call on the record Checkpoint: Creditor notice window closes on the internal Umwandlungsgesetz merger registered at Amtsgericht Jena

The call

A steady hardware maker sheltered inside a patient private parent, facing established lab-instrument rivals rather than AI, with an internal 2026 merger the main thing to watch.

Analytik Jena builds machines that test and measure things in laboratories and factories, owned since 2016 by Endress+Hauser, a larger Swiss company that is itself family-owned and profitable. Rivals like Thermo Fisher and Agilent are much bigger, but they cannot easily copy Analytik Jena's equipment because labs buy based on regulatory approval, long-term reliability, and the fact that switching costs money and time; AI tools can help interpret data or manage labs, but they cannot replace the physical machines themselves. The one thing to watch is a planned restructuring in June 2026 at the Jena court that might show whether the parent company is merging Analytik Jena's operations into bigger units or keeping it separate, that move could signal whether the parent sees it as a keeper or is consolidating it away.

Why

AI pressure: None apparent. AI-based LIMS and spectral-ID software help chemists read results faster but cannot replace the physical AAS/ICP-MS hardware Analytik Jena sells. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific, Agilent Technologies, Shimadzu. All three already sell competing ICP-MS and AAS lines with far larger R&D budgets and global service networks. Could a giant copy it? Probably.

What protects it. Wholly owned by profitable, family-controlled Endress+Hauser since 2016, so it gets stable funding without pressure to chase quarterly numbers or an exit.

What would change this call

Completion of June 2026 Umwandlungsgesetz merger registered at Amtsgericht Jena. Would reveal whether Analytik Jena is being consolidated or deprioritized within Endress+Hauser.
Endress+Hauser issues a material downward revision to its FY2025 mid-single-digit growth guidance. Would signal group-level pressure that could reduce R&D or hiring at Analytik Jena.
Thermo Fisher, Agilent, or Shimadzu launch next-gen ICP-MS or AAS products in 2026-2027. Would show whether rivals can neutralize Analytik Jena's HR-CS AAS or ICP-MS differentiation.

Key numbers

~1,000-1,100 employees, flat for about a decade (2016-12-08)
Parent Endress+Hauser revenue: EUR3.72B (2023)
Analytik Jena legal entity revenue: EUR140.7M (2021)

Named risks

Internal Umwandlungsgesetz merger registered June 2026 could signal function consolidation within Endress+Hauser. Severity: medium
Mid-tier scale (est. EUR140.7M in 2021) versus giants like Thermo Fisher at ~$24.4B limits pricing and R&D leverage. Severity: medium
No independent capital path since 2016 takeover; strategic direction fully subordinate to Endress+Hauser priorities. Severity: low
Conflicting revenue figures across sources create opacity around true standalone financial health. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	losing to	~$24.4B revenue vs Analytik Jena's fraction of that, per 2024-05-18 ICP-MS market report
Agilent Technologies	contesting	IP cross-license negotiations after AJ's 2014 Bruker ICP-MS acquisition, FTC filing 2018
Shimadzu Corporation	losing to	~$3.2B revenue dwarfs AJ's scale in ICP-MS/AAS market, 2024-05-18 report
Bruker Corporation	contesting	AJ's ICP-MS line originated from Bruker's divested ICP-MS unit acquired 2014
PerkinElmer	contesting	Named alongside AJ as alternative in 2026-01-08 ICP-MS buyer's guide comparisons

Questions people ask

Who owns Analytik Jena AG?: Analytik Jena has been a wholly owned subsidiary of Switzerland's family controlled Endress+Hauser Group since a squeeze out completed around January to March 2016, when Endress+Hauser held 96.18 percent and paid EUR13.68 per remaining share. It delisted from the Frankfurt Stock Exchange on 27 March 2015.
Is Analytik Jena profitable?: No standalone profit figure is disclosed. Parent Endress+Hauser Group reported EUR3.72 billion revenue for FY2023 and said it maintained sales and profits at high levels in 2024, guiding mid single digit sales growth for 2025, but Analytik Jena's own contribution is not broken out.
Could AI replace Analytik Jena's lab instruments?: Unlikely in the near term. Analytik Jena's value sits in proprietary hardware like HR-CS AAS spectrometers and ICP-MS plasma sources plus regulatory method validation (USP, EPA). AI can augment its LIMS software (LABbase, readyLIMS) and spectral interpretation, but cannot replace physical instrumentation or installed-base service lock-in.
Who are Analytik Jena's biggest competitors?: Thermo Fisher Scientific (about $24.4 billion revenue), Agilent Technologies (about $4.9 billion), Shimadzu Corporation (about $3.2 billion), PerkinElmer, and Bruker Corporation, per a 2024-05-18 ICP-MS market report. These rivals are 15 to 170 times larger than Analytik Jena by revenue.
What is Analytik Jena's revenue?: The Analytik Jena legal entity reported EUR140.7 million revenue in FY2021 with 581 employees, per a Wikipedia infobox citation. This figure likely reflects the German parent entity only, not consolidated worldwide sales; no more recent standalone figure has been published.
Has Endress+Hauser considered spinning off Analytik Jena?: No divestiture or spin-off has been announced. A merger or restructuring transaction for Analytik Jena GmbH+Co. KG was registered in Germany's commercial register on 2026-06-11 under the Umwandlungsgesetz, with a six month creditor notice window, but this appears to be an internal reorganization, not a sale.

Timeline

2026-06-11Merger/restructuring for Analytik Jena GmbH+Co. KG registered at Amtsgericht Jena under Umwandlungsgesetz
2026-06-04Announced faster fluorine analysis method for pyrolysis-oil vs crude-oil refinery risk analysis
2026-03-17Celebrated 40 years of subsidiary Biometra, molecular biology instruments
2025-08-25Cited growth in Brazil and Latin America; formed new Brazilian entity
2025-02-20Joined EU/Thuringia funded ZirKat project on battery raw material recycling
2025-02-12Integrated SPECORD PLUS UV/Vis devices with external LMS via updated ASpect UV software
2024-04-12Launched multi N/C x300, clinPAL, and qTOWER iris product lines at Analytica 2024
2016-01-03Endress+Hauser completed full takeover of Analytik Jena
2015-09Endress+Hauser launched squeeze-out at EUR13.68 per share, holding 96.18 percent
2015-03-27Analytik Jena AG delisted from Frankfurt Stock Exchange

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE